NCT05236972View on ClinicalTrials.gov

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2028

Conditions
Colorectal Carcinoma
Interventions
DRUG

Sintilimab

Sintilimab 200mg iv drip Q3W

DRUG

Oxaliplatin

130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.

DRUG

capecitabine

1000 mg/m² po twice daily on days 1- 14 repeated every 21 days

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

West China Hospital

OTHER

lead

Sun Yat-sen University

OTHER